Cargando…
A plea to provide best evidence in trials under sample-size restrictions: the example of pioglitazone to resolve leukoplakia and erythroplakia in Fanconi anemia patients
In planning a clinical trial for demonstrating the efficacy of pioglitazone to resolve leukoplakia and erythroplakia in Fanconi anemia patients we had to discuss the need for a randomized controlled trial particularly under sample-size restrictions as very promising results were available from a sin...
Autores principales: | Lasch, Florian, Weber, Kristina, Chao, Mwe Mwe, Koch, Armin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445360/ https://www.ncbi.nlm.nih.gov/pubmed/28545482 http://dx.doi.org/10.1186/s13023-017-0655-8 |
Ejemplares similares
-
Clinical management guidelines for Friedreich ataxia: best practice in rare diseases
por: Corben, Louise A., et al.
Publicado: (2022) -
Critical appraisal of arguments for the delayed-start design proposed as alternative to the parallel-group randomized clinical trial design in the field of rare disease
por: Spineli, Loukia M., et al.
Publicado: (2017) -
Optimising the diagnosis and referral of achondroplasia in Europe: European Achondroplasia Forum best practice recommendations
por: Cormier-Daire, Valerie, et al.
Publicado: (2022) -
Clinical development innovation in rare diseases: lessons learned and best practices from the DevelopAKUre consortium
por: Rudebeck, Mattias, et al.
Publicado: (2021) -
Oral Erythroplakia and Speckled Leukoplakia: retrospective analysis of 13 cases
por: Hosni, Elaini Sickert, et al.
Publicado: (2015)